


About Albemarle Asset Management

Albemarle Asset Management was founded in London in 2003. The company provides both individual and collective management services for private and institutional investors, financial and capital management consultancy, and managed investment solutions. Our services cover global financial markets and our expertise enables us to offer diverse set of investment instruments and strategies.


Performance

	YTD	1M	3YR	5YR	Inception
Fund	2.74%	4.86%	-0.73%	24.82%	63.29%
Benchmark	-2.09%	1.73%	1.94%	13.08%	34.64%
	Best Mth	Worst Mth	CAGR	Vol	Sharpe R.
Fund	18.26%	-23.04%	4.98%	25.28%	0.23
Benchmark	15.35%	-15.56%	2.99%	26.93%	0.16

Chart Performance



Returns



Fund Objective

Albemarle Target Europe Fund is a sub-fund of Albemarle Funds Plc an open-ended investment company with variable capital incorporated in Ireland. The investment objective of the sub-fund is to achieve long term capital appreciation by investing in the European equity market.

Fund Information


Company	Albemarle Funds Plc
Investment Manager	Albemarle Asset Management Ltd
Bloomberg	ATLTEUI ID
ISIN	IE00B502PK59
Inception	21/01/2011
Currency	EUR
Fund Manager	Albemarle Asset Management Ltd
Management Fees	0.80% p.a.
Benchmark	90% of MSCI EMU
Performance Fees	25% of the value which exceeds the benchmark return of 90% of the MSCI EMU Index
NAV	Daily
Cut-Off	T-1 before 1pm Irish Ti The Fund posted
Stlmt date for sub.	T+2 Irish Business Days
Stlmt date for red.	T+2 Irish Business Days
Domicile	Ireland
Auditors	Grant Thornton
Depository	Northern Trust Fiduciary Services (Ireland) Ltd
Category	UCITS V

Important Information

The information contained within this document is for the use of Institutional and Professional Investors only

Source: Bloomberg


Sector Breakdown Net Exposure (%)




Top Holdings

Arnoldo Mondadori	5.10%
Esprinet	4.99%
Pirelli	4.67%
Fila	4.35%
Danone	4.30%
Total	23.41%

Asset Allocation Exposure



Country Breakdown Net Exposure



Commentary

The Fund posted a positive performance in December, outperforming again its benchmark. The main positive contributors to the Fund performance had been Esprinet, Hunting Plc, Fila, Rheinmetall and Jacquet Metals. Esprinet continued to rise given the good momentum and some analysts upgrading their target price on the stock. Hunting rose thanks to firmer oil prices and a trading update which showed good cash generation in Q4 2020 and some modest signs of recovery looking at the year 2021. Rheinmetall outperformed partially closing the underperformance accumulated towards other German industrial companies also thanks to the positive newsflow regarding order intake in Q4 2020. The main detractors to the Fund performance during the month had been Piovan, Pirelli and Cementir. Pirelli had been under pressure for technical reasons after the issue of a new convertible bond. Cementir suffered some profit-taking after the very strong performance registered in November. During the month the main trades executed had been the sale of Esprinet, Titan Cement, Ebro Foods and Tinexta, and the purchase of El.en, Buzzi, Piovan, Sanofi and Mersen.

Disclaimer

This information is being communicated by Albemarle Asset Management Limited, which is authorised and regulated by the Financial Conduct Authority. This material is for information only and does not constitute an offer or recommendation to buy or sell any investment, or subscribe to any investment management or advisory service. It is only directed and may only be distributed to persons who are Professional Clients or Eligible Counterparties and is not, under any circumstances, intended for distribution to the general public. With investment, your capital is at risk and the value of an investment and the income from it can go up as well as down, it may be affected by exchange rate variations and you may not get back the amount invested. Past performance is not necessarily a guide to future performance. We do not represent that this information, including any third party information, is accurate or complete and it should not be relied upon as such. Opinions expressed herein reflect the opinion of Albemarle Asset Management Limited and are subject to change without notice. No part of this document may be reproduced in any manner without the written permission of Albemarle Asset Management Limited, however recipients may pass on this document but only to others falling within this category. This information should be read in conjunction with the relevant fund documentation which may include the fund's prospectus, simplified prospectus or supplement documentation and if you are unsure if any of the products and portfolios featured are the right choice for you, please seek independent financial advice provided by regulated third parties.